Off Editas’ shelves, iNK cell therapies float to Shoreline

Editas Medicine is offloading its iNK cell franchise and licensing out some gene editing tech to a private biotech that counts BeiGene and Gilead’s Kite as friends. Shoreline Biosciences is buying EDIT-202 and another undisclosed iNK program as part of the deal. MiNK Therapeutics had also been vying for the…

...

Click to view original post